The limitations of sequential submissions are no longer theoretical—they are structural, measurable, and increasingly untenable.
For decades, regulatory execution has followed a market-by-market approach. What began as a practical necessity has become a systemic constraint. As global expansion accelerates and pressure on speed and efficiency intensifies, the consequences of this model are becoming harder to ignore.
When submissions move sequentially, the impact extends far beyond timelines.
Drug lag increases, delaying patient access not because of science or safety, but because of process. Approvals cascade one market at a time, compounding delays across regions and extending the time it takes for therapies to reach patients globally.
At the same time, lifetime revenue is reduced. Each delay pushes approvals further into the product lifecycle, shortening the window for full commercialization. Lost time at the front end of global rollout translates directly into lost value.
Patent protection is also eroded. While submissions progress sequentially, the patent clock continues to run. Protected time is consumed without corresponding access, compressing return on R&D investment and weakening the economics of innovation.
Operationally, cost rises as duplication becomes embedded in the process. Regulatory teams repeat the same work across markets—authoring, responding, and revalidating—shifting effort away from strategy toward process management.
And perhaps most importantly, portfolio velocity slows. When resources are tied up executing submissions one at a time, fewer products, variations, and expansions can move forward in parallel, limiting global scale and increasing concentration risk.
But the most critical consequence is this: patients wait.
These delays are not evenly distributed. Patients in low- and middle-income countries often experience the longest gaps—waiting years for access to therapies that are already approved, safe, and available elsewhere. Sequential models reinforce disparities that modern regulatory systems are increasingly capable of eliminating.
A New Operating Standard Is Emerging
The industry is now at an inflection point.
Simultaneous submissions—supported by shared visibility and coordinated review across markets—are redefining what regulatory execution can look like. This model replaces multi-year, wave-based timelines with parallel engagement, enabling approvals in months rather than years.
What was once constrained by feasibility is now enabled by infrastructure.
Leading organizations are no longer focused on managing sequential execution. They are optimizing for global regulatory performance—executing across markets in parallel, with coordination rather than delay.
When supported by fit-for-purpose digital infrastructure, simultaneous submissions unlock a fundamentally different set of capabilities:
1. Regulatory reliance becomes operational, not theoretical
When multiple regulatory authorities receive the same submission at the same time, reliance can be applied during review—not just after approval. Insights, questions, and assessments can inform parallel reviews, reducing duplication while preserving independent decision-making.
2. Review cycles run in parallel rather than in series
Instead of waiting for approvals to cascade, reviews proceed concurrently. Timelines shift from cumulative to overlapping, dramatically accelerating the path to global approval.
3. Redundant work is reduced across markets
Shared visibility into submissions and responses minimizes repeated authoring and rework. Regulatory effort is focused where it adds value, rather than reproducing the same activities market by market.
4. Global timelines are compressed by years
What historically required multiple years through wave submissions can now be achieved in a fraction of the time—protecting product value and increasing portfolio throughput.
5. Patients gain access sooner, regardless of geography
By enabling earlier approvals across regions, simultaneous submissions reduce disparities in access—particularly in markets that have traditionally experienced the longest delays.
From Constraint to Choice
Technology is no longer the limiting factor.
The shift from sequential to simultaneous is ultimately a shift in mindset: from managing process to enabling performance, from local execution to global coordination, from delay as a constraint to speed as a system capability.
But at its core, this is not just an operational decision—it is a patient one.
Every month gained in regulatory timelines is a month patients receive treatment sooner. Every market reached in parallel is a population no longer asked to wait its turn. And every reduction in duplication is an opportunity to focus more effort on delivering safe, effective therapies where they are needed most.
The future of regulatory submissions will not be defined by how efficiently we manage delay, but by how effectively we eliminate it for patients everywhere.Now is the time to act.
If you’re exploring how to transition from sequential execution to a simultaneous model, click below to learn more.